Department of Anesthesiology and Pain Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.
Eur J Anaesthesiol. 2012 Nov;29(11):520-3. doi: 10.1097/EJA.0b013e3283565267.
Muscle relaxants used to facilitate tracheal intubation have disadvantages.
This study was designed to evaluate the dose requirements for remifentanil combined with thiopental for optimal lightwand intubation without muscle relaxants.
Prospective randomised controlled study.
A tertiary care teaching hospital.
Ninety-six patients requiring general anaesthesia for elective surgery.
Patients received remifentanil 1, 2, or 3 μg kg(-1) (group R1, R2, R3, each n = 32) as a slow bolus infusion over 60 s, followed by thiopental 5 mg kg(-1). Ninety seconds after remifentanil administration, lightwand intubation was attempted and intubation time was recorded. Intubating conditions were considered excellent if there was no patient movement or cough, good if coughing occurred once or twice after intubation and poor if persistent movement or cough occurred after intubation. Excellent or good intubating conditions were regarded as clinically acceptable. The duration of apnoea was recorded.
Intubating conditions and the duration of apnoea.
Lightwand intubation was successful at the first attempt in all patients except for two in group R1. The intubating conditions were more acceptable in groups R2 and R3 than in group R1 (97 and 100 vs. 63%, P < 0.01). Intubation time was shorter in group R3 than in group R1 (22 ± 8 vs. 33 ± 18 s, P < 0.01). There was no significant difference in intubation time and conditions between groups R2 and R3. The mean duration of apnoea was prolonged in group R3 compared with group R2 (10.2 ± 2.1 vs. 4.6 ± 1.6 min, P < 0.01).
Our results suggest that remifentanil 2 or 3 μg kg(-1) combined with thiopental 5 mg kg provides acceptable conditions for lightwand intubation without muscle relaxants. Spontaneous ventilation returns more rapidly following remifentanil 2 μg kg(-1) than with remifentanil 3 μg kg(-1).
用于促进气管插管的肌肉松弛剂有其缺点。
本研究旨在评估瑞芬太尼联合硫喷妥钠在不使用肌肉松弛剂的情况下进行光棒插管的最佳剂量需求。
前瞻性随机对照研究。
一家三级护理教学医院。
需要全身麻醉进行择期手术的 96 名患者。
患者接受瑞芬太尼 1、2 或 3μgkg-1(组 R1、R2、R3,每组 n=32)作为 60 秒的缓慢推注,然后给予硫喷妥钠 5mgkg-1。瑞芬太尼给药后 90 秒尝试进行光棒插管,并记录插管时间。如果没有患者移动或咳嗽,则插管条件被认为是极好的;如果插管后仅发生一次或两次咳嗽,则插管条件被认为是良好的;如果插管后持续发生移动或咳嗽,则插管条件被认为是较差的。极好或良好的插管条件被认为是临床可接受的。记录无通气时间。
插管条件和无通气时间。
除组 R1 中的两名患者外,所有患者均在首次尝试时成功进行了光棒插管。组 R2 和 R3 的插管条件优于组 R1(97%和 100%比 63%,P<0.01)。组 R3 的插管时间短于组 R1(22±8 比 33±18 秒,P<0.01)。组 R2 和 R3 之间的插管时间和条件无显著差异。与组 R2 相比,组 R3 的无通气时间延长(10.2±2.1 比 4.6±1.6 分钟,P<0.01)。
我们的结果表明,瑞芬太尼 2μgkg-1或 3μgkg-1联合硫喷妥钠 5mgkg-1可提供在不使用肌肉松弛剂的情况下进行光棒插管的可接受条件。与瑞芬太尼 3μgkg-1相比,瑞芬太尼 2μgkg-1 后自主通气恢复更快。